Surrozen (SRZN) EBITDA (2020 - 2026)
Surrozen (SRZN) recorded quarterly EBITDA of -$10.5 million in Q1 2026, up 17.27% quarter-over-quarter from -$12.6 million in Q4 2025, and down 9.48% on a YoY basis from -$11.6 million in Q1 2025.
Surrozen (SRZN) EBITDA (2020 - 2026) Analysis & Trends
Surrozen's EBITDA history runs 7 years deep, the most recent figure standing at -$10.5 million for Q1 2026.
- In Q1 2026, EBITDA fell 9.48% year-over-year to -$10.5 million; the TTM figure through Mar 2026 stood at -$43.0 million (up 33.12% YoY), while the FY2025 annual figure was -$42.1 million, up 33.78% from the prior year.
- EBITDA was -$10.5 million for Q1 2026 at Surrozen, up from -$12.6 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$592000.0 in Q4 2022 to a low of -$28.0 million in Q4 2024.
- Historically, EBITDA has averaged -$11.5 million across 5 years, with a median of -$10.4 million in 2023.
- The sharpest annual moves came in 2022 and 2023: EBITDA jumped 96.07% in 2022, then sank 1405.74% in 2023.
- A 5-year view of EBITDA shows it stood at -$592000.0 in 2022, then tumbled by 1405.74% to -$8.9 million in 2023, then plunged by 214.55% to -$28.0 million in 2024, then jumped by 54.92% to -$12.6 million in 2025, then climbed by 17.27% to -$10.5 million in 2026.
- The last three EBITDA figures came in at -$10.5 million (Q1 2026), -$12.6 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.46 Mn |
| Dec 31, 2025 | -12.64 Mn |
| Sep 30, 2025 | -10.89 Mn |
| Jun 30, 2025 | -9.02 Mn |
| Mar 31, 2025 | -9.55 Mn |
| Dec 31, 2024 | -28.04 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -25.26 Mn |
| Mar 31, 2024 | -8.83 Mn |
| Dec 31, 2023 | -8.91 Mn |
| Sep 30, 2023 | -10.45 Mn |
| Jun 30, 2023 | -9.33 Mn |
| Mar 31, 2023 | -14.11 Mn |
| Dec 31, 2022 | -592,000.00 |
| Sep 30, 2022 | -13.31 Mn |
| Jun 30, 2022 | -13.97 Mn |
| Mar 31, 2022 | -8.26 Mn |
| Dec 31, 2021 | -15.06 Mn |
| Sep 30, 2021 | -14.04 Mn |
| Jun 30, 2021 | -12.65 Mn |